Tofacitinib citrate CAS NO.540737-29-9
- FOB Price: USD: 20.00-20.00 /Metric Ton Get Latest Price
- Min.Order: 1 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Available Specifications:
99%(500-1000)Metric Ton
- Product Details
Keywords
- Tofacitinib citrate
- Tofacitinib citrate
- Tofacitinib citrate
Quick Details
- ProName: Tofacitinib citrate
- CasNo: 540737-29-9
- Molecular Formula: C16H20N6O.C6H8O7
- Appearance: white powder
- Application: rheumatic arthritis
- DeliveryTime: in 7 days
- PackAge: 25KG/drum
- Port: Shanghai/Beijing/Tianjin
- ProductionCapacity: 10 Metric Ton/Year
- Purity: 99%
- Storage: Room temperature
- Transportation: Regular transportation
- LimitNum: 1 Kilogram
- Related Substances: 0.1%
- Residue on Ignition: 0.1%
- Heavy Metal: 10ppm
- Valid Period: 3 years
Superiority
Why is SINOWAY:
1) Specialized in pharmaceutical and healthcare industrial for 34 years.
2) ISO 9001:2015 & SGS audited supplier .
3) Accept various payment terms : T.T 30-60 days.
4) We have warehouse in USA with quickly shipment .
5) We can do different terms of FOB ,CIF/CIP ,DDP ...
Why choose us
1. best quality in your requirement
2. competitive price in china market
3. mature technical support
4. professional logistic support
5. full experience of large numbers containers loading in chinese sea port
6. fast shipment by reputed shipping line
7. packing with pallet as buyer's special request
8. best service after shipment with email !
9. cargoes together with container after-sales service available
10. full experience in export
11. raw materials from chinese origin
Details
the information of Tofacitinib citrate CAS:540737-29-9:
Product name |
Tofacitinib citrate |
CAS No. |
540737-29-9 |
Molecular Formula |
C16H20N6O.C6H8O7 |
Molecular Weight |
504.497 |
Quality Standard |
99% up, Medicine Grade |
Appearance |
White powder |
The COA of Tofacitinib citrate CAS:540737-29-9:
The use of Tofacitinib citrate CAS:540737-29-9:
Tofacitinib citrate in combination with methotrexate is used for the treatment of active rheumatoid arthritis with inadequate response to tumor necrosis factor inhibitors.